Gestala

Gestala operates at the intersection of neurotechnology, medical devices, and brain–computer interfaces, with an emphasis on ultrasound rather than relying solely on conventional electrical interfaces. Its described portfolio spans functional ultrasound imaging and focused-ultrasound neuromodulation, with benchtop, wearable, and implantable product directions. The Diadem system is positioned for non-invasive deep-brain neuromodulation, including research into chronic pain and depression. A stated differentiator is its Relative Through-Transmit approach, designed to measure and compensate for skull-induced ultrasound attenuation and phase shifts without requiring additional imaging. The company also identifies MEMS, AI, and acoustic-sensitive proteins among its technology areas. This breadth suggests an effort to combine sensing, targeting, and device engineering rather than focus on a single interface component. Its market position is best described as a specialized ultrasound-neurotechnology developer; clinical validation, regulatory progress, product availability, and adoption data are not established here.

The available financing history indicates activity across 2026: a CNY 150 million Seed round dated March 12, followed by two recorded Angel+ entries—$62 million on July 3 and RMB 430 million on July 8. Together, those entries imply approximately $142.6 million when the CNY amounts are converted at an approximate rate of 7.2 CNY per USD, but the two closely dated Angel+ amounts may overlap and should not be read as a confirmed cumulative total without clarification. The product and technology description points to a development strategy extending beyond one device: Diadem targets non-invasive deep-brain neuromodulation, while functional ultrasound imaging and benchtop, wearable, and implantable lines broaden the intended platform scope. The stated RTT method addresses skull-related ultrasound distortion, a technical challenge relevant to transcranial applications. The financing entries and multi-product ambitions are visible inflection points, while regulatory progress, commercialization, and clinical adoption remain unverified.